

## SUBSTANTIAL HOLDERS

---

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, 'ARO A' or the 'Company') provides the following information regarding its substantial shareholders.

Under New Zealand law, there is no requirement for a shareholder of the Company to issue a substantial shareholding notice of holdings above 5%. As the Company is a New Zealand company, the Australian law regarding substantial shareholder notices does not apply to the Company. However, a shareholder may voluntarily disclose such information if it chooses to do so and a number of New Zealand companies that are listed on ASX experience shareholders lodging notices similar to a substantial shareholder notice that is required under Australian law notwithstanding that there is no requirement to do so.

Separately, the Company has undertaken to inform the ASX on becoming aware of a person becoming a substantial shareholder, a movement of at least 1% of shares in which a substantial shareholder has a relevant interest and a person ceasing to be a substantial shareholder.

Accordingly, following the successful completion of the placement of 40,343,348 ordinary shares on 4 August 2021 and further to a change in holdings of Phil McCaw and Movac Fund 3 LP on 9 August 2021, to the best of the Company's knowledge, its substantial shareholders as of 9 August 2021 are as follows:

Holder Name	Securities Held	Percentage Holding
BRIAN WARD & TRACEY WARD <ARAWAI NO 2 A/C>	33,125,800	9.702%
CITICORP NOMINEES PTY LIMITED	27,365,874	8.015%
J P MORGAN NOMINEES AUSTRALIA PTY LIMITED	24,401,862	7.147%
NATIONAL NOMINEES LIMITED	22,112,806	6.477%
PHIL MCCAW <MCSYTH CAPITAL INVESTMENT A/C> and <MCSYTH CHARITABLE A/C>*	19,669,229	5.761%

\* Phil McCaw's holding increased by 2,864,879 on 9 August 2021 as reported in Appendix 3Y due to an in specie distribution from Movac Fund 3 LP.

< ENDS >

**Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.**

### About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company that develops, manufactures, sells and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Committed to 'unlocking regenerative healing for everybody', its products are developed from the Company's proprietary Aroa ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Aroa's products have been used in more than four million procedures to date, with distribution into its key market of the United States by its direct sales force and its partner TELA Bio, Inc. Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX). [www.aroabio.com/](http://www.aroabio.com/)

**Contacts**

*Investor*

Simon Hinsley  
Investor Relations  
[shinsley@aroabio.com](mailto:shinsley@aroabio.com)  
+ 61 401 809 653

*Media*

Australia

Matthew Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 451 896 420

New Zealand

Piet De Jong  
[piet.dejong@baldwinboyle.com](mailto:piet.dejong@baldwinboyle.com)  
+64 21 812 766